

Lupin gets approval for anti-allergy drug

22 May 2017 | News

Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian Pharmaceutical Market (IPM), which could benefit millions of patients suffering from allergic symptoms.



Drug firm Lupin has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Bepotastine tablets used in the treatment of patients suffering from allergic symptoms.

Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian Pharmaceutical Market (IPM), which could benefit millions of patients suffering from allergic symptoms.

It is a rapid acting antihistamine that effectively controls day time and night time triggers of allergic symptoms. Bepotastine is approved by PMDA Japan and is actively marketed in Japan and other South-East Asian countries.

The current market for plain antihistamines is estimated to be around Rs. 860 crore, growing at 14 per cent.